Pain Assessment and Quality of Life in Back Pain Patients: Role of Milnacipran
Status:
Withdrawn
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
1. To show that patients with greater pain sensitivity will show greater improvement in
their symptoms (self-reported pain intensity, mood, sleep, and quality of life) than
those with lower pain sensitivity, based on QST, after taking milnacipran.
2. To compare outcome differences (pain intensity, mood, activity interference, sleep, and
side effects) with those patients who are either taking or not taking opioids for their
pain 10 weeks after being prescribed milnacipran.
3. To show that patients who are older, male, with more medical comorbidities, greater
disability, and longer pain duration will report less improvement (pain, mood, sleep,
health-related quality of life) and treatment satisfaction while taking milnacipran
compared with others without such characteristics.